Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Merck and Co Inc | 701 |
| 2 | Takeda Pharmaceutical Co Ltd | 404 |
| 3 | Daiichi Sankyo Co Ltd | 191 |
| 4 | Eli Lilly and Co | 164 |
| 5 | Bristol Myers Squibb Co | 93 |
| 6 | AbbVie Inc | 75 |
| 7 | Biora Therapeutics Inc | 70 |
| 8 | Takasago International Corp | 65 |
| 9 | Pfizer Inc | 60 |
| 10 | University of California | 50 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 2,300 |
| 2 | C07D | Heterocyclic compounds | 2,179 |
| 3 | A61K | Medicinal preparations | 2,000 |
| 4 | Y02P | Climate change mitigation: production | 729 |
| 5 | C07F | Organometallic compounds | 622 |
| 6 | C12N | Microorganisms, enzymes | 606 |
| 7 | C07C | Acyclic and carbocyclic compounds | 358 |
| 8 | C07K | Peptides | 345 |
| 9 | Y02A | Climate change adaptation | 308 |
| 10 | C12P | Fermentation, enzyme processes | 304 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Substituted N-methylene derivatives of thienamycin | 1980 | Merck and Co Inc | 88 |
| Crystalline N-formimidoyl thienamycin | 1981 | Merck and Co Inc | 57 |
| Thienamycin renal peptidase inhibitors | 1992 | Merck and Co Inc | 39 |
| Process for the preparation of thienamycin and intermediates | 1980 | Merck and Co Inc | 33 |
| Synthesis of thienamycin via trans-3-carboxymethylene-4-carboxy-5-methyl-Δ2 -isoxazoline | 1981 | Merck and Co Inc | 31 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2021 | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Gloria Blanco | Universidad de Oviedo | 5 |
| 2 | Byron H. Arison | Merck & Co., Inc., Rahway, NJ, USA (United States) | 4 |
| 3 | Edward Inamine | Merck & Co., Inc., Rahway, NJ, USA (United States) | 4 |
| 4 | Alfredo F. Braña | Universidad de Oviedo | 4 |
| 5 | Craig A. Townsend | Johns Hopkins University | 4 |
| 6 | Cármen Méndez | Universidad de Oviedo | 3 |
| 7 | Jerrold M. Liesch | Merck & Co., Inc., Rahway, NJ, USA (United States) | 3 |
| 8 | Joanne M. Williamson | Merck & Co., Inc., Rahway, NJ, USA (United States) | 3 |
| 9 | Michael F. Freeman | Johns Hopkins University | 3 |
| 10 | Christopher J. Schofield | University of Oxford | 3 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Metabolism of Thienamycin and Related Carbapenem Antibiotics by the Renal Dipeptidase, Dehydropeptidase-I | 1982 | 340 | Antibiotic Resistance in Bacteria |
| Carbapenems, a new class of beta-lactam antibiotics | 1985 | 293 | Antibiotic Resistance in Bacteria |
| Empirical antibacterial drug discovery—Foundation in natural products | 2006 | 243 | Microbial Natural Products and Biosynthesis |
| Secretion systems for secondary metabolites: how producer cells send out messages of intercellular communication | 2005 | 203 | Microbial Natural Products and Biosynthesis |
| Biosynthesis of fluorothreonine and fluoroacetic acid by the thienamycin producer, Streptomyces cattleya. | 1986 | 164 | Microbial Natural Products and Biosynthesis |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of thienamycin?
Which companies hold the most patents related to thienamycin?
What notable research has been published on thienamycin metabolism?
What are the main patent classification areas for thienamycin intellectual property?
How has patent activity for thienamycin trended in recent years?